Clinical Cancer Drugs publishes original research, full-length reviews/ mini reviews, and thematic issues in all core areas of translational and clinical cancer drug research.
The journal publishes pre-clinical and clinical studies on the development of new anti-cancer agents. Clinical studies of new reported anti-cancer drugs include Phase 1–IV clinical trial studies, their designs, research methodologies, and analyses. The journal is essential reading for clinical oncologists, toxicologists, medicinal chemists, and pharmacologists.
Bianca Maria Veneziani, Micaela Montanari, Maria Letizia Cataldo, Luigi Coppola, Agostina Nardone, Sara Corvigno, Carmine De Angelis, Grazia Arpino, Mario Giuliano, Chiara Carlomagno, Roberto Bianco and Sabino De Placido
Dr. Francia began his career by undertaking a PhD with Dr. Ian Hart at the Imperial Cancer Research Fund in London, UK, which has since evolved into Cancer UK. After his PhD, he trained with Dr. Robert Kerbel in Toronto, Canada, on aspects of metastasis, therapies for metastatic disease, and tumor resistance to therapy. He is now Assistant Professor at The University of Texas at El Paso, where he is attempting to set up a research program that is internationally recognized for pioneering new cancer therapeutic ideas, and for generating in vivo models to help translate laboratory findings into the clinic - by developing new metastatic tumor models, and by refining those he has already established.